Trials / Completed
CompletedNCT02964936
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
A Phase 3, Multicenter, Randomized, 2-Arm, Open-label Study of Intermittent Oral Dosing of ASP1517 for the Treatment of Anemia in Erythropoiesis Stimulating Agent-untreated Chronic Kidney Disease Patients Not on Dialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | roxadustat | Oral administration |
Timeline
- Start date
- 2017-01-11
- Primary completion
- 2018-08-15
- Completion
- 2018-08-15
- First posted
- 2016-11-16
- Last updated
- 2024-10-31
Locations
38 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02964936. Inclusion in this directory is not an endorsement.